Precision BioSciences announces results from low-dose cohort of ECUR-506

iECURE announced positive results from a preliminary analysis of the completed low-dose cohort of ECUR-506 from the ongoing OTC-HOPE clinical trial in neonatal-onset ornithine transcarbamylase, OTC, deficiency. Data were presented at the Society for Inherited Metabolic Disorders, SIMD, 2026 Annual Meeting. The first infant treated with ECUR-506 demonstrated a durable clinical response, with sustained discontinuation of standard-of-care therapies and no hyperammonemic events through 18 months post dose, as of February 11, 2026. In addition, participants treated with the low dose of ECUR-506 experienced statistically significant reductions in the annualized rates of HAEs and hyperammonemic crises, with 57% and 65% reductions, respectively, in pre-dose to post-dose rates of events per person-year, as of April 20, 2026.